Pfizer (NYSE:PFE) has entered into a multi-year collaboration with Alloy Therapeutics to develop a new antibody discovery platform. Under the deal, Alloy will receive an upfront payment from ...

Alloy Therapeutics Inc. (Alloy), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced its latest strategic collaboration with ...

Moderna was dealt a significant blow in the patent battle over who owns the Covid-19 vaccine last week. In the U.S., the Cambridge drug and vaccine maker hit a roadblock when the Patent Trial and ...

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against ...

Pfizer offers a substantial 6.7% dividend yield and has increased its dividend for 16 consecutive years. The stock trades at a forward P/E of just 8.7, close to historical lows. Despite policy ...

Collaboration builds on Alloy’s existing and highly productive engagement with Pfizer and will apply Alloy’s innovation expertise to address Pfizer’s specific antibody discovery objectives BOSTON, ...